收费全文 | 182198篇 |
免费 | 1337篇 |
国内免费 | 42篇 |
耳鼻咽喉 | 1194篇 |
儿科学 | 7017篇 |
妇产科学 | 3180篇 |
基础医学 | 17463篇 |
口腔科学 | 1909篇 |
临床医学 | 13015篇 |
内科学 | 32276篇 |
皮肤病学 | 851篇 |
神经病学 | 17093篇 |
特种医学 | 9065篇 |
外科学 | 29670篇 |
综合类 | 2359篇 |
一般理论 | 4篇 |
预防医学 | 18488篇 |
眼科学 | 2866篇 |
药学 | 9840篇 |
中国医学 | 647篇 |
肿瘤学 | 16640篇 |
2023年 | 52篇 |
2022年 | 125篇 |
2021年 | 244篇 |
2020年 | 127篇 |
2019年 | 200篇 |
2018年 | 22118篇 |
2017年 | 17501篇 |
2016年 | 19702篇 |
2015年 | 1116篇 |
2014年 | 1013篇 |
2013年 | 1096篇 |
2012年 | 7431篇 |
2011年 | 21448篇 |
2010年 | 19068篇 |
2009年 | 11759篇 |
2008年 | 19861篇 |
2007年 | 22084篇 |
2006年 | 887篇 |
2005年 | 2512篇 |
2004年 | 3702篇 |
2003年 | 4594篇 |
2002年 | 2746篇 |
2001年 | 341篇 |
2000年 | 452篇 |
1999年 | 220篇 |
1998年 | 246篇 |
1997年 | 255篇 |
1996年 | 135篇 |
1995年 | 135篇 |
1994年 | 119篇 |
1993年 | 102篇 |
1992年 | 68篇 |
1991年 | 121篇 |
1990年 | 157篇 |
1989年 | 110篇 |
1988年 | 84篇 |
1987年 | 80篇 |
1986年 | 49篇 |
1985年 | 63篇 |
1984年 | 47篇 |
1983年 | 48篇 |
1982年 | 49篇 |
1980年 | 66篇 |
1974年 | 32篇 |
1970年 | 34篇 |
1969年 | 39篇 |
1938年 | 65篇 |
1934年 | 38篇 |
1932年 | 66篇 |
1930年 | 57篇 |
Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxiety disorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the Cochrane Library.
Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However, vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclear whether the drug’s dual mechanism of action provides greater efficacy than prevailing treatment options. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety in larger and more diverse populations. Although vilazodone may have an additional advantage for the treatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacy over and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodone should be considered as a second- or third-line treatment option for MDD and GAD. 相似文献
Methods: In this prospective observational study, 15 volunteers underwent sciatic nerve examination using a curved ultrasound probe in the range of 2-5 MHz and a Philips-ATL 5000 unit (ATL Ultrasound, Bothell, WA) in the gluteal, infragluteal, and proximal thigh regions. Thereafter, an insulated block needle was advanced inline with the ultrasound beam to reach the nerve target, which was further confirmed by electrical stimulation. The quality of sciatic nerve images, ease of needle to nerve contact, threshold stimulating current, and resultant motor response were recorded.
Results: The sciatic nerve was successfully identified in the transverse view as a solitary predominantly hyperechoic structure on ultrasound in all of the three regions examined. The target nerve was visualized easily in 87% and localized within two needle attempts in all patients. Nerve stimulation was successful in 100% after two attempts with a threshold current of 0.42 +/- 0.12 (mean +/- SD) eliciting foot plantarflexion or dorsiflexion. 相似文献